摘要
目的观察多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效和安全性。方法40例晚期非小细胞肺癌患者应用多西他赛（75mg／m2，第1天）联合顺铂（25mg／m2，静脉滴注，第1～3天）化疗，21d为1个周期，连续应用2个周期后采用WHO标准进行化疗效果评价。结果4JD例患者中部分缓解16例（40．0％）、稳定17例（42．5％）、进展7例（17．5％），近期有效率为40．0％（16／40），中位生存期11．8个月。不良反应以骨髓抑制、关节肌肉疼痛和消化道反应为主，均对症治疗后缓解，未发生严重不良反应。结论多西他赛联合顺铂治疗晚期非小细胞肺癌有较好的疗效，不良反应少。
Objective To observe the efficacy and safety of docetaxel and cisplatin in treatment of advanced non-small cell lung cancer. Methods 40 patients with advanced non-small cell lung cancer were treated with docetaxel （75 mg/m2 , day 1 ） combined with cisplatin with chemotherapy ,21 d to a cycle of continuous application of two cycles of chemotherapy using WHO criteria evaluation. Results 40 patients, partial remission in 16 cases （40. 0% ）, stable in 17 cases（42.5% ） ,progress in 7 cases（ 17.5% ） ,the recent rate was 40.0% （16/40） ,median survival was 11.8 months. Adverse reactions such as bone marrow depression ,joint and muscle pain and gastrointestinal reactions, were relieved after symptomatic treatment, no serious adverse reactions . Conclusion Docetaxel and cisplatin treatment of advanced non-small cell lung cancer had better efficacy ,fewer side effects.
出处
《中国基层医药》
CAS
2010年第21期2921-2922,共2页
Chinese Journal of Primary Medicine and Pharmacy
关键词
癌
非小细胞肺
多西他赛
顺铂
Carcinoma, non-small-cell lung
Docetaxel
Cisplatin
